In a murine model of atopic dermatitis, subcutaneous injections of EVs derived from IFN-γ-primed MSCs were administered once weekly for 5 weeks, starting from the second week after the initial application of 0.4% DNCB, a disease-inducing agent. Here, IFNG is linked to atopic eczema.